Managing heart failure with mildly reduced or preserved ejection fraction presents a multifaceted clinical challenge. Patients frequently exhibit complex cardiovascular and metabolic comorbidities, notably elevated systemic blood pressure. Consequently, the utility of finerenone in HFpEF has emerged as a major therapeutic consideration for clinicians managing difficult-to-treat phenotypes. In particular, apparent treatment-resistant hypertension significantly compounds the risk of recurrent hospital admissions, functional decline, and cardiovascular mortality. A new prespecified analysis from the landmark FINEARTS-HF trial provides critical evidence regarding how this nonsteroidal mineralocorticoid receptor antagonist performs in patients with concurrent resistant hypertension and heart failure. These data clarify whether baseline blood pressure status influences the therapeutic benefits of mineralocorticoid receptor blockade.

The Burden of Apparent Treatment-Resistant Hypertension in HFmrEF and HFpEF

Apparent treatment-resistant hypertension represents a severe vascular phenotype characterized by uncontrolled blood pressure despite concurrent therapy with three or more antihypertensive drug classes, one of which is a diuretic. Alternatively, clinicians identify this condition when blood pressure control requires four or more distinct antihypertensive medications. In the FINEARTS-HF trial, investigators observed that approximately one in eight participants (12.9%) presented with this high-risk condition at baseline. Furthermore, nearly 30% of the cohort demonstrated non-resistant uncontrolled hypertension, whereas 57.8% maintained controlled blood pressure values.

Patients who suffer from resistant hypertension typically endure accelerated target-organ damage across cardiovascular and renal vascular beds. Excessive mineralocorticoid receptor activation, vascular stiffness, persistent neurohormonal dysregulation, and insidious sodium retention collectively exacerbate myocardial strain. Consequently, these pathological processes drive adverse left ventricular remodeling and progressive diastolic dysfunction. Although these patients receive complex multidrug regimens, achieving target blood pressure goals remains exceptionally difficult in routine clinical practice. Therefore, clinicians urgently need targeted disease-modifying therapies. Specifically, treatments must address both neurohormonal overactivation and vascular resistance without precipitating adverse hemodynamic instability, abrupt glomerular filtration decline, or severe electrolyte derangements.

Key Findings on Finerenone in HFpEF Across Blood Pressure Strata

The prespecified analysis evaluated whether baseline hypertension categories modified the therapeutic efficacy of finerenone compared to placebo. Over a median follow-up period extending up to 36 months, finerenone achieved consistent systolic blood pressure reductions across all baseline blood pressure categories. Importantly, the interaction testing confirmed that the magnitude of blood pressure lowering did not differ significantly between patients with controlled blood pressure, non-resistant hypertension, and apparent treatment-resistant hypertension.

Moreover, the trial demonstrated that the relative clinical benefits of finerenone remained robust regardless of baseline blood pressure status. Rates of cardiovascular death and total heart failure events were 17.0 per 100 person-years in the controlled blood pressure group, 16.0 in the non-resistant hypertension group, and 13.8 in the resistant hypertension group. When researchers evaluated the primary composite endpoint, they observed consistent risk reductions across all three subgroups without significant statistical interaction. In addition, finerenone significantly improved heart failure-related health status and quality-of-life scores, as measured by the Kansas City Cardiomyopathy Questionnaire. Thus, the evidence confirms that finerenone delivers meaningful clinical and symptomatic improvements even among individuals with refractory hypertension.

Mechanistic Insights: Nonsteroidal Mineralocorticoid Receptor Blockade

The distinct pharmacology of finerenone explains its favorable dual impact on cardiovascular outcomes and systemic hemodynamic parameters. Unlike traditional steroidal mineralocorticoid receptor antagonists such as spironolactone and eplerenone, finerenone functions as a bulky, nonsteroidal antagonist. It binds competitively and selectively to the mineralocorticoid receptor, preventing cofactor recruitment and effectively suppressing proinflammatory and profibrotic gene transcription.

In heart failure with preserved or mildly reduced ejection fraction, aldosterone-driven signaling accelerates myocardial interstitial fibrosis, microvascular rarefaction, and central arterial stiffness. Consequently, these structural alterations impede ventricular filling, elevate systemic vascular resistance, and worsen exercise intolerance. By providing balanced tissue distribution between cardiac tissue and renal parenchyma, finerenone attenuates interstitial collagen deposition, enhances endothelial nitric oxide bioavailability, and mitigates systemic inflammation. In addition, finerenone promotes modest natriuresis, which assists in systemic decongestion and facilitates sustained blood pressure control. Because the drug does not engage androgenic or progestogenic receptors, it completely avoids endocrine adverse effects such as gynecomastia. Therefore, this nonsteroidal mechanism provides an optimized balance of cardioprotection, renoprotection, and vascular modulation.

Safety, Tolerability, and Potassium Monitoring in Clinical Practice

The FINEARTS-HF trial demonstrated that the safety and tolerability profile of finerenone remained consistent across all baseline hypertension categories. Notably, patients with apparent treatment-resistant hypertension did not experience a disproportionate increase in serious adverse events when randomized to finerenone compared to placebo. Because many of these patients already receive multiple neurohormonal inhibitors and diuretics, establishing safety in this vulnerable cohort provides substantial reassurance to treating physicians.

Nevertheless, clinicians must recognize that mineralocorticoid receptor antagonism inherently increases the potential risk of hyperkalemia. In routine clinical practice, physicians should carefully evaluate baseline serum potassium concentrations and estimated glomerular filtration rates prior to treatment initiation. Finerenone is typically prescribed at 20 mg or 40 mg once daily based on baseline renal function, provided serum potassium remains at or below 5.0 mmol/L. Subsequently, structured biochemical monitoring at four weeks after drug initiation and periodically thereafter allows for rapid identification of potassium elevations. Concomitant therapy with sodium-glucose cotransporter-2 inhibitors also helps mitigate hyperkalemia risks. Therefore, proactive laboratory surveillance and individualized dose adjustments allow clinicians to safely maintain therapy while maximizing clinical benefits.

Clinical Implications for Multidisciplinary Cardiovascular Care

The identification of apparent treatment-resistant hypertension in one out of every eight individuals with HFmrEF or HFpEF highlights a critical clinical challenge. Hypertension represents the dominant etiologic driver for the development and progression of heart failure with preserved ejection fraction. Consequently, cardiologists, nephrologists, internists, and primary care physicians must adopt an integrated, multidisciplinary approach to comprehensive diagnostic screening, therapeutic intensification, and longitudinal monitoring.

Furthermore, these trial findings confirm that finerenone serves a dual therapeutic purpose in this complex patient population. It acts not only as an effective adjunctive blood pressure-lowering agent but also as a proven disease-modifying therapy that reduces heart failure hospitalizations and cardiovascular mortality. Rather than viewing blood pressure control and heart failure care as separate clinical targets, physicians can utilize nonsteroidal mineralocorticoid receptor antagonism to address shared neurohormonal and vascular pathways. Incorporating finerenone alongside sodium-glucose cotransporter-2 inhibitors establishes a potent, synergistic foundational regimen. Ultimately, expanding the use of finerenone helps optimize functional capacity, enhance health-related quality of life, and substantially reduce avoidable cardiovascular hospitalizations in clinical practice.

Frequently Asked Questions

How does finerenone differ from traditional steroidal mineralocorticoid receptor antagonists?

Finerenone is a next-generation nonsteroidal mineralocorticoid receptor antagonist characterized by high receptor selectivity and balanced tissue distribution between the heart and kidneys. Unlike steroidal agents such as spironolactone and eplerenone, finerenone does not interact with androgen or progesterone receptors. Consequently, it avoids adverse hormonal effects like gynecomastia or breast tenderness. Additionally, its unique receptor binding mode potent suppresses inflammatory and fibrotic signaling while conferring a lower risk of severe hyperkalemia in heart failure populations.

Can finerenone effectively lower blood pressure in patients with resistant hypertension?

Yes, prespecified findings from the FINEARTS-HF trial demonstrate that finerenone significantly reduces systolic blood pressure across all baseline blood pressure categories, including apparent treatment-resistant hypertension. By selectively inhibiting mineralocorticoid receptor overactivation, finerenone reduces vascular resistance, promotes modest natriuresis, and attenuates arterial stiffness. Consequently, it provides meaningful hemodynamic improvement alongside its established cardioprotective benefits, helping clinicians achieve better systemic blood pressure control in patients whose hypertension remains uncontrolled despite multiple standard antihypertensive medications.

What safety monitoring is required when initiating finerenone in heart failure patients?

Clinicians should evaluate baseline serum potassium concentrations and estimated glomerular filtration rates before starting finerenone. The medication should be initiated only if serum potassium is 5.0 mmol/L or lower. Follow-up laboratory assessments of serum potassium and renal function are essential at four weeks after initiation or dose escalation, and periodically thereafter. Furthermore, patient education on dietary potassium intake and prompt dose adjustments during acute intercurrent illnesses ensure safe, long-term administration in heart failure patients.

Disclaimer: This content is for informational and educational purposes only, and does not constitute medical advice, diagnosis, or treatment recommendations. Healthcare professionals should exercise independent clinical judgment and cross-reference information with relevant institutional policies, peer-reviewed literature, and official prescribing information. Refer to the latest local and national guidelines for clinical practice.

References

1. Ostrominski JW et al. Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction. Eur J Heart Fail. 2026 Aug 17. doi: undefined. PMID: 42606500.


2. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-1485.


3. Ostrominski JW, Claggett BL, Kulac IJ, et al. Finerenone and Blood Pressure in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial. JAMA Cardiol. 2026; doi: 10.1001/jamacardio.2026.2104.